Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.43 |
| ▸ | DHFR | P00374 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | LCAT | P04180 | 2/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20255191 | 0.89 | HRH4 (0.43) | MAPTCYP3A4HRH3DHFRGPR119 | |
| SCHEMBL20249098 | 0.86 | MAPT (0.46) | MAPTCYP3A4HRH3DHFRGPR119 | |
| SCHEMBL20249101 | 0.84 | HRH4 (0.51) | CYP3A4HRH3DHFR | |
| SCHEMBL20255106 | 0.83 | HRH4 (0.44) | CYP3A4HRH3 | |
| SCHEMBL20224120 | 0.83 | CYP3A4 (0.47) | CYP3A4HRH3DHFR | |
| SCHEMBL22601459 | 0.83 | MAPT (0.50) | MAPTHRH3DHFRHSD11B1 | |
| SCHEMBL20249223 | 0.83 | HRH4 (0.39) | CYP3A4HRH3DHFR | |
| SCHEMBL20249224 | 0.83 | HRH4 (0.39) | CYP3A4HRH3DHFR | |
| SCHEMBL14008911 | 0.82 | POLB (0.55) | MAPTHSD11B1POLB | |
| SCHEMBL16256660 | 0.81 | MAPT (0.53) | MAPTDHFRHSD11B1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CDK4, CDK6, CDK16 | MAPT 2551/4885CYP3A4 539/4885HRH3 2304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.